The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School: Carcinoma trials
The registry lists 11 Carcinoma studies with The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School as lead sponsor. 7 are open to participants now and 0 have results posted.
Phase 1 2Phase 2 6Phase 3 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological TumorsNot yet recruitingNCT06221774Phase 1/2
- Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary CarcinomaNot yet recruitingNCT06062485Phase 2
- Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence FactorsRecruitingNCT05768464Phase 2
- Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal ImageRecruitingNCT05627297
- The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal CarcinomaNot yet recruitingNCT04769076Phase 2
- Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal CarcinomaNot yet recruitingNCT04766359Phase 3
- Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver TransplantationRecruitingNCT04595864Phase 3
- Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor SamplesStatus unknownNCT05171439Phase 2
- Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell CarcinomaCompletedNCT04535687Phase 2
- GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCCStatus unknownNCT04121273Phase 1
- Endoscopic Robot-Assisted Simple Enucleation Versus Standard Robot-Assisted Partial Nephrectomy in the Treatment of T1 Renal Cell CarcinomaActive, not recruitingNCT03624673Not applicable